Skip to main content
Caplight Logo









Antegenes

Antegenes

Private
TartuHealthcare & Life Scienceshttps://antegenes.com/

Last Round

Grant

Aug 2, 2022

Total Funding Raised

$2.91M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Antegenes is a health technology company that develops and provides polygenic risk score-based genetic tests for the personalized prevention and early detection of common cancers.

Sector

Healthcare & Life Sciences

Verticals

Precision Medicine, Biotechnology, Healthcare Analytics

Business Model

B2B2C

Customer Profile

Usage-Based SaaS, Services & Consulting

AI Layer

Application

Keywords

polygenic risk scorePRSgenetic testingprecision medicineclinical decision supportgenetic risk assessmentpreventive screeninggenomicspersonalized medicinepredictive healthDNA testinghealth techcancer screeninggenetic counselingIVD

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Antegenes Comparables

Compare Antegenes with similar companies based on industry and business-model similarity.

Antegenes comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
GENinCode PLC
81%
Allelica, Inc.
80%
Genetic Technologies Limited
76%

Antegenes Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantAug 2, 2022
GrantAug 2, 2022
SeedAug 2, 2022
SeedNov 9, 2021

Key People

Founding team and executive leadership

Jagnar Pindmaa

Chief Technology Officer

Executive Team

Anna Padrik

Acting COO

Executive Team

Berit Kolk

Chief Operating Officer

Executive Team

Akshay Mody

Chief Medical Officer General Manager UK, Non Executive Board Member

Executive Team

Antegenes Investors

Notable investors and investment history

Antegenes investors
InvestorRounds
EIT HealthGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 20, 2026

    Monthly visitors increased 45% MoM, reaching 1.1K.

  • May 19, 2026

    Monthly visitors increased 53% MoM.

Antegenes Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Antegenes Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Antegenes's valuation, stock price, and market status.

Firmographic Details

HeadquartersTartu
Employee Range11
Year Founded2018
Last FundingAug 2, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?